Record Net Sales of DARZALEX for Q3, 2024
In an exciting announcement, Genmab A/S reported impressive net sales of its drug DARZALEX (daratumumab) for the third quarter of 2024, totaling USD 3,016 million. This remarkable figure highlights the growing acceptance and demand for this innovative treatment, which continues to enhance patient care in the oncology sector.
Understanding DARZALEX Sales Performance
During this quarter, net sales were split with USD 1,684 million generated in the U.S. market and USD 1,332 million from other international markets. Genmab benefits from a collaboration with Janssen Biotech, Inc., which manages the development, manufacturing, and commercialization of daratumumab. These robust sales figures underline the strength of the partnership and the growing global market for monoclonal antibody therapies.
The Subcutaneous Variant: DARZALEX FASPRO
Notably, part of these sales includes the subcutaneous variant of DARZALEX, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj). This formulation offers new options for patients, allowing for a more convenient administration compared to the traditional intravenous version. This shift not only benefits patients seeking easier treatment options but also contributes to the overall sales success.
Genmab’s Strategic Vision
With over 25 years of dedication to biotechnology, Genmab is guided by a mission to advance the lives of patients through innovative antibody therapeutics. Their efforts have led to the development of an extensive pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint inhibitors. This commitment underscores their vision to transform cancer treatment through groundbreaking therapies.
Company History and Global Reach
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has extended its reach globally, establishing a presence in North America, Europe, and Asia Pacific. This international footprint allows the company to enhance its collaborations, thereby accelerating the development of its innovative therapies and expanding access to its life-changing drugs.
Future Directions and Innovations
As Genmab looks towards 2030, their vision encompasses delivering extraordinary antibody medicines that aim to significantly improve the quality of life for those living with cancer and other serious conditions. This focus on long-term patient outcomes illustrates the company's dedication to not just therapeutic advancements but also patient well-being.
Contact and Additional Information
For further inquiries, Genmab's senior leadership team is available for contact. Marisol Peron, Senior Vice President of Global Communications, can be reached at +1 609 524 0065, while Andrew Carlsen, Vice President of Investor Relations, is contactable at +45 3377 9558. They are keen to share insights and updates about their mission and projects.
Frequently Asked Questions
What is DARZALEX and its primary uses?
DARZALEX (daratumumab) is a monoclonal antibody primarily used to treat multiple myeloma, a type of cancer affecting plasma cells.
How did Genmab's sales perform in Q3 2024?
Genmab reported net sales of USD 3,016 million for DARZALEX in Q3 2024, with significant contributions from both U.S. and international markets.
What is the difference between DARZALEX and DARZALEX FASPRO?
DARZALEX is administered intravenously, while DARZALEX FASPRO includes a subcutaneous formulation, allowing for easier administration.
Where is Genmab headquartered?
Genmab is headquartered in Copenhagen, Denmark, with a notable global presence across various regions.
What are Genmab's goals for the future?
Genmab aims to enhance the lives of cancer patients through innovative antibody therapies, aspiring to provide extraordinary therapeutic options by 2030.
